vs
ICU MEDICAL INC（ICUI）与Ubiquiti Inc.（UI）财务数据对比。点击上方公司名可切换其他公司
Ubiquiti Inc.的季度营收约是ICU MEDICAL INC的1.5倍（$814.9M vs $540.7M），Ubiquiti Inc.净利率更高（28.7% vs -2.9%，领先31.6%），Ubiquiti Inc.同比增速更快（35.8% vs -14.1%），Ubiquiti Inc.自由现金流更多（$260.3M vs $36.0M），过去两年Ubiquiti Inc.的营收复合增速更高（28.6% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
Ubiquiti Inc.是一家美国科技企业，2003年于加利福尼亚州圣何塞成立，目前总部位于纽约。公司旗下拥有多个品牌，主营面向企业及家庭用户的有线、无线数据通信产品的研发、生产与销售。
ICUI vs UI — 直观对比
营收规模更大
UI
是对方的1.5倍
$540.7M
营收增速更快
UI
高出50.0%
-14.1%
净利率更高
UI
高出31.6%
-2.9%
自由现金流更多
UI
多$224.3M
$36.0M
两年增速更快
UI
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $814.9M |
| 净利润 | $-15.7M | $233.6M |
| 毛利率 | 37.5% | 45.9% |
| 营业利润率 | 1.0% | 35.9% |
| 净利率 | -2.9% | 28.7% |
| 营收同比 | -14.1% | 35.8% |
| 净利润同比 | 34.0% | 70.8% |
| 每股收益（稀释后） | $-0.63 | $3.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIUI
| Q4 25 | $540.7M | $814.9M | ||
| Q3 25 | $537.0M | $733.8M | ||
| Q2 25 | $548.9M | $759.2M | ||
| Q1 25 | $604.7M | $664.2M | ||
| Q4 24 | $629.8M | $599.9M | ||
| Q3 24 | $589.1M | $550.3M | ||
| Q2 24 | $596.5M | $507.5M | ||
| Q1 24 | $566.7M | $493.0M |
净利润ICUIUI
| Q4 25 | $-15.7M | $233.6M | ||
| Q3 25 | $-3.4M | $207.9M | ||
| Q2 25 | $35.3M | $266.7M | ||
| Q1 25 | $-15.5M | $180.4M | ||
| Q4 24 | $-23.8M | $136.8M | ||
| Q3 24 | $-33.0M | $128.0M | ||
| Q2 24 | $-21.4M | $103.8M | ||
| Q1 24 | $-39.5M | $76.3M |
毛利率ICUIUI
| Q4 25 | 37.5% | 45.9% | ||
| Q3 25 | 37.4% | 46.0% | ||
| Q2 25 | 37.9% | 45.1% | ||
| Q1 25 | 34.7% | 44.5% | ||
| Q4 24 | 36.1% | 41.2% | ||
| Q3 24 | 34.8% | 42.1% | ||
| Q2 24 | 34.8% | 40.2% | ||
| Q1 24 | 32.7% | 35.3% |
营业利润率ICUIUI
| Q4 25 | 1.0% | 35.9% | ||
| Q3 25 | 2.6% | 35.7% | ||
| Q2 25 | 1.9% | 34.4% | ||
| Q1 25 | 2.1% | 34.2% | ||
| Q4 24 | 6.0% | 29.8% | ||
| Q3 24 | 1.4% | 30.7% | ||
| Q2 24 | 1.3% | 27.3% | ||
| Q1 24 | -1.9% | 22.6% |
净利率ICUIUI
| Q4 25 | -2.9% | 28.7% | ||
| Q3 25 | -0.6% | 28.3% | ||
| Q2 25 | 6.4% | 35.1% | ||
| Q1 25 | -2.6% | 27.2% | ||
| Q4 24 | -3.8% | 22.8% | ||
| Q3 24 | -5.6% | 23.3% | ||
| Q2 24 | -3.6% | 20.5% | ||
| Q1 24 | -7.0% | 15.5% |
每股收益（稀释后）ICUIUI
| Q4 25 | $-0.63 | $3.86 | ||
| Q3 25 | $-0.14 | $3.43 | ||
| Q2 25 | $1.43 | $4.40 | ||
| Q1 25 | $-0.63 | $2.98 | ||
| Q4 24 | $-0.97 | $2.26 | ||
| Q3 24 | $-1.35 | $2.12 | ||
| Q2 24 | $-0.88 | $1.72 | ||
| Q1 24 | $-1.63 | $1.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $302.8M |
| 总债务越低越好 | — | $47.5M |
| 股东权益账面价值 | $2.1B | $1.0B |
| 总资产 | $4.1B | $1.6B |
| 负债/权益比越低杠杆越低 | — | 0.05× |
8季度趋势，按日历期对齐
现金及短期投资ICUIUI
| Q4 25 | — | $302.8M | ||
| Q3 25 | — | $177.2M | ||
| Q2 25 | — | $149.7M | ||
| Q1 25 | — | $151.0M | ||
| Q4 24 | $308.6M | $133.1M | ||
| Q3 24 | $312.5M | $165.2M | ||
| Q2 24 | $302.6M | $126.3M | ||
| Q1 24 | $251.4M | $102.5M |
总债务ICUIUI
| Q4 25 | — | $47.5M | ||
| Q3 25 | — | $133.8M | ||
| Q2 25 | — | $250.0M | ||
| Q1 25 | — | $340.0M | ||
| Q4 24 | — | $406.3M | ||
| Q3 24 | — | $552.5M | ||
| Q2 24 | — | $708.1M | ||
| Q1 24 | — | $877.5M |
股东权益ICUIUI
| Q4 25 | $2.1B | $1.0B | ||
| Q3 25 | $2.1B | $828.4M | ||
| Q2 25 | $2.1B | $668.3M | ||
| Q1 25 | $2.0B | $436.1M | ||
| Q4 24 | $2.0B | $290.4M | ||
| Q3 24 | $2.0B | $188.1M | ||
| Q2 24 | $2.0B | $95.1M | ||
| Q1 24 | $2.1B | $25.9M |
总资产ICUIUI
| Q4 25 | $4.1B | $1.6B | ||
| Q3 25 | $4.1B | $1.5B | ||
| Q2 25 | $4.1B | $1.5B | ||
| Q1 25 | $4.2B | $1.3B | ||
| Q4 24 | $4.2B | $1.2B | ||
| Q3 24 | $4.3B | $1.2B | ||
| Q2 24 | $4.3B | $1.2B | ||
| Q1 24 | $4.3B | $1.2B |
负债/权益比ICUIUI
| Q4 25 | — | 0.05× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.37× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 2.94× | ||
| Q2 24 | — | 7.45× | ||
| Q1 24 | — | 33.92× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $263.9M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $260.3M |
| 自由现金流率自由现金流/营收 | 6.6% | 31.9% |
| 资本支出强度资本支出/营收 | 4.6% | 0.4% |
| 现金转化率经营现金流/净利润 | — | 1.13× |
| 过去12个月自由现金流最近4个季度 | $91.8M | $699.5M |
8季度趋势，按日历期对齐
经营现金流ICUIUI
| Q4 25 | $60.6M | $263.9M | ||
| Q3 25 | $56.7M | $198.5M | ||
| Q2 25 | $11.2M | $130.4M | ||
| Q1 25 | $51.3M | $123.6M | ||
| Q4 24 | $40.2M | $152.4M | ||
| Q3 24 | $36.1M | $233.7M | ||
| Q2 24 | $82.0M | $231.4M | ||
| Q1 24 | $45.8M | $163.9M |
自由现金流ICUIUI
| Q4 25 | $36.0M | $260.3M | ||
| Q3 25 | $27.6M | $193.3M | ||
| Q2 25 | $-8.5M | $125.2M | ||
| Q1 25 | $36.7M | $120.7M | ||
| Q4 24 | $16.1M | $150.4M | ||
| Q3 24 | $16.2M | $231.1M | ||
| Q2 24 | $62.5M | $229.5M | ||
| Q1 24 | $29.9M | $160.6M |
自由现金流率ICUIUI
| Q4 25 | 6.6% | 31.9% | ||
| Q3 25 | 5.1% | 26.3% | ||
| Q2 25 | -1.5% | 16.5% | ||
| Q1 25 | 6.1% | 18.2% | ||
| Q4 24 | 2.6% | 25.1% | ||
| Q3 24 | 2.7% | 42.0% | ||
| Q2 24 | 10.5% | 45.2% | ||
| Q1 24 | 5.3% | 32.6% |
资本支出强度ICUIUI
| Q4 25 | 4.6% | 0.4% | ||
| Q3 25 | 5.4% | 0.7% | ||
| Q2 25 | 3.6% | 0.7% | ||
| Q1 25 | 2.4% | 0.4% | ||
| Q4 24 | 3.8% | 0.3% | ||
| Q3 24 | 3.4% | 0.5% | ||
| Q2 24 | 3.3% | 0.4% | ||
| Q1 24 | 2.8% | 0.7% |
现金转化率ICUIUI
| Q4 25 | — | 1.13× | ||
| Q3 25 | — | 0.95× | ||
| Q2 25 | 0.32× | 0.49× | ||
| Q1 25 | — | 0.68× | ||
| Q4 24 | — | 1.11× | ||
| Q3 24 | — | 1.83× | ||
| Q2 24 | — | 2.23× | ||
| Q1 24 | — | 2.15× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
UI
| Enterprise Technology | $729.0M | 89% |
| Service Provider Technology | $85.9M | 11% |
